shares were up following an announcement that the company is enrolling patients in trials involving its proposed obesity drug Lorcaserin. The trial is one of three phase III studies evaluating the safety and efficacy of the drug. Shares rose 1.1% to $11.58.
( STGN) jumped following the release of the results from a Food and Drug Administration study on the quality control of genetic-testing microarrays.
"Stratagene's Universal Reference RNA was one of two high-quality reference standards selected as part of the
FDA's MicroArray Quality Control project," said Dr. Joseph Sorge, Stratagene's president and CEO. "These reference RNAs allow laboratories with many different microarray platforms to compare and share data in the global microarray community." Shares grew 10.9% to $4.78.
rose after investment research firm Jefferies & Co. initiated coverage of the stock with a buy rating. Analyst Brian Wright also set a target price for the company's stock at $75. Shares were trading up 2.7% to $64.28.
said a U.S. District Court judge dismissed a shareholder complaint regarding the company's alleged breaches of its duties related to the cancer drug Xyotax. Shares rose 2.9% to $1.70.
advanced after it appointed Matthew Hogan as chief financial officer. Hogan has 10 years of experience as a CFO at Ciphergen Biosystems, Avocet Medical and Microcide Pharmaceuticals and was previously an investment banker at
( MER). Durect's shares were up 2.7% to $3.86.
dipped after the Food and Drug Administration posted a warning letter on its Web site on violations regarding the company's quality-control systems. Shares were lower by 20 cents, or 0.4%, to $46.65.
Also on the move were
( GENZ), down 20 cents to $65.03,
, off 22 cents to $63.23, and
, lower by 6 cents, or 3.7%, to $1.56.
was up 1.4% to $55,
was gaining 1.6% to $56.13,
( QSC) was rising 6.8% to $1.72,
( IMM) was up 3.4% to $5.21, and
was climbing 1.3% to $22.80.